News

Oculis Expands Loan Facility for Advanced Biopharmaceutical Development

Oculis Expands Loan Facility for Advanced Biopharmaceutical Development

Oculis Secures Expanded Loan Facility

Oculis Holding AG (NASDAQ: OCS) has announced an important update regarding its financial strategy. The global biopharmaceutical company, known for its commitment to addressing unmet medical needs in ophthalmology and neuro-ophthalmology, has successfully amended its loan facility. This new agreement, established with funds and accounts managed by BlackRock, allows Oculis to access up to CHF 100 million, affording significant financial flexibility for the future.

Details of the Amended Loan Agreement

The Amended Loan Agreement supersedes the previous loan arrangement that was set in place on May 29, 2024. The upsized structure of this loan provides an initial borrowing capacity of CHF 75 million, which has the potential to increase to CHF 100 million. This flexible funding arrangement consists of tranches allocated at CHF 25 million each, with an additional tranche of up to CHF 25 million potentially available upon mutual agreement with the Lender. Notably, no amounts were drawn upon signing, indicating Oculis' strategic approach in managing its cash flows.

Financial Flexibility and Strategic Milestones

Access to this additional capital is poised to boost Oculis' operational flexibility, ensuring that the company can effectively navigate its financial landscape as it pursues critical milestones for its projects. Currently, Oculis is focused on advancing its three core assets: it is in active regulatory discussions with the FDA regarding three indications using Privosegtor (OCS-05), aimed at treating acute optic neuritis, non-arteritic anterior ischemic optic neuritis (NAION), and acute relapses in multiple sclerosis (MS), with significant developments expected in the latter half of 2025. In the same period, Oculis will also initiate the Phase 2/3 trials for Licaminlimab (OCS-02) targeting dry eye disease.

CEO's Perspective on Financial Developments

Riad Sherif, M.D., the Chief Executive Officer of Oculis, expressed satisfaction regarding the increased loan agreement. He stated, "We are pleased to have upsized our previous loan agreement with funds managed by BlackRock. This expansion allows us enhanced flexibility that ensures our future financial and operational strength. Our robust cash position provides runway into early 2028, further strengthened by this loan facility as we focus on advancing our portfolio of differentiated assets. Our goal is to bring transformative treatments to patients in need." This commitment showcases Oculis' dedication to innovation and patient care.

Understanding Oculis: A Brief Overview

Oculis Holding AG operates as a biopharmaceutical entity keenly focused on innovative treatments for ophthalmic and neuro-ophthalmic conditions where significant unmet medical needs exist. The company boasts a highly differentiated late-stage clinical pipeline featuring three core product candidates. OCS-01 is under pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema. Meanwhile, Privosegtor (OCS-05) is a first-in-class neuroprotective candidate currently in Phase 2 trials for acute optic neuritis, potentially applicable to numerous neuro-ophthalmic conditions. Licaminlimab (OCS-02), designed with a personalized medicine approach, is being developed as a novel topical anti-TNF? for addressing dry eye disease (DED).

Contacting Oculis for More Information

For inquiries regarding Oculis, Ms. Sylvia Cheung, Chief Financial Officer, can be reached at sylvia.cheung@oculis.com. Additionally, for investor relations, Corey Davis, Ph.D., can be contacted through cdavis@lifesciadvisors.com. Media relations inquiries can be directed to Amber Fennell, David Daley, or Sean Leous at oculis@icrhealthcare.com. Oculis emphasizes transparency and is committed to communicating effectively with its stakeholders.

Frequently Asked Questions

What is the significance of the amended loan agreement for Oculis?

The amended loan agreement enhances Oculis' financial flexibility, allowing for increased funding that supports its critical projects and clinical trials.

How much capital can Oculis access through this agreement?

Oculis can access up to CHF 100 million through the amended loan facility, which significantly bolsters its operational resources.

What are the key projects Oculis is focusing on?

Oculis is advancing three core assets: OCS-01 for diabetic macular edema, Privosegtor (OCS-05) for acute optic neuritis, and Licaminlimab (OCS-02) for dry eye disease.

What is the role of BlackRock in Oculis' financing?

BlackRock acts as the lender for the amended loan facility, which provides Oculis with the financial tools needed to further develop its innovative treatments.

Who can be contacted for further inquiries about Oculis?

Inquiries can be directed to Sylvia Cheung for financial matters, Corey Davis for investor relations, and ICR Healthcare for media-related questions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Helio Genomics Shakes Up Liver Cancer Detection Strategy

Updated Category News Views 5

Rethinking Liver Cancer Detection with HelioLiver Sometimes you stumble upon a tech piece that might genuinely shake up the game. Helio Genomics just poured some serious intel at the San Antonio Liver Cancer Symposium, showcasing how their HelioLiver Dx might outgun traditional scans in sniffing out hepatocellular carcinoma (HCC). They threw down four studies revealing...

Continue Reading
Mastering Packaging Costs: Beyond the Box Price

Updated Category News Views 4

Peeling Back the Layers of Packaging Costs Packaging's a bit like an onion—every layer you peel back reveals another cost you didn’t see at first glance. Folks in the know, like Kyle Reger of Jamestown Container Companies, are flipping the script on how we approach packaging expenses. It's not just about snagging the cheapest box on the shelf anymore. There's a whole...

Continue Reading
Chianti Classico Showcases 2027 Vintages in Florence

Updated Category News Views 4

A Grand Reunion of the Black Rooster You're not just sipping wine at a garden party—you're diving into a historic event. Come March 1-2, 2027, Florence will again host the much-anticipated Chianti Classico Collection, uniting over 200 eager producers under the iconic vaults of Stazione Leopolda. This isn't just another stop on the wine circuit; it's a pilgrimage to the...

Continue Reading
BETR Faces Securities Fraud Actions Post-Misleading Statements

Updated Category News Views 3

Unpacking the Legal Drama Around BETR The tale of Better Home & Finance Holding Company (BETR) is like a roadside crash you can't help but stare at. We're talking big, ugly losses and a chance for investors who got roughed up to throw some punches back with a securities fraud class action. The legal honchos at Howard G. Smith's law office are rallying the troops. If...

Continue Reading
Greenberg Traurig Nabs Major Award for Sukuk Deal

Updated Category News Views 4

Legal brands winning awards might seem like just another day in the office, but when a firm like Greenberg Traurig snags the Impact Deal of the Year at the IFLR Middle East Awards, it deserves more than just a shrug. We're talking about a serious feather in the cap for their Capital Markets team, who played a key role in launching Binghatti's hefty USD 1.5 billion Sukuk...

Continue Reading
CellFiber Expands to Philly: Boosting US Biotech Scene

Updated Category News Views 5

CellFiber's Leap into 'Cellicon Valley' Folks, when the biotech winds start blowing, you better have your sails up. CellFiber Co., Ltd., a Tokyo-based innovator, has landed itself a comfy spot in the City of Brotherly Love. We're talking Philadelphia, folks, or, as it's dubbed in certain circles, 'Cellicon Valley.' Now if that's not a name that screams biotech pedigree, I...

Continue Reading
Strategic Move: Chimney Collective Teams with Four Winds

Updated Category News Views 5

A Partnership Fueled by Legacy and Growth In the world of brick, mortar, and flue, a big play just unfolded. Chimney Collective, flexing its investment muscle, has hitched its wagon to Four Winds Chimney, a company that's carved out quite a niche in New York's chimney scene. We're not talking about a corporate takeover here; this is about putting money where growth and...

Continue Reading
Elevest Unveils MADE: Shaping Wealth for Athletes, Artists

Updated Category News Views 4

Turning Talent Into Tangible Wealth Ask any musician or athlete, and they'll tell you—riding those career highs is exhilarating, but financial stability can be a different ballgame. Here comes Elevest Capital with a fresh move meant to set the players right where many falter: long-term ownership. They're rolling out MADE, a new initiative focused on flipping that burst...

Continue Reading
Toyland 2026: Blain's 'Open The Magic' Event Marks 69 Years

Updated Category News Views 5

There's something about nostalgia that hooks you right in the gut, like remembering those jittery walks through Blain's Farm & Fleet's Toyland aisles. If there's one thing these folks know, it's how to spark holiday cheer deep in the Midwest bones. Here we are, just before the dust settles on another year, and Blain's is rolling out its 69th Toyland party—a cherished...

Continue Reading
Navigating Career Growth Beyond Job Titles at Webinar

Updated Category News Views 5

Hasn't it ever struck you that job titles often fence people in like some unwanted corral, keeping potential tightly leashed? Well, here's something that might shake up your thoughts a tad. University of Phoenix is teeing up a webinar titled "Beyond The Job Title: Finding Purpose and Recognizing the Value You Bring." Scheduled for October 15, 2026, this is all about...

Continue Reading

Top 5 Most Recently Viewed Articles

Disguise Enhances Partnership with Aniplex for Demon Slayer Costumes

Updated Category News Views 141

Disguise Expands Licensing Agreement with Aniplex Disguise, Inc., the innovative costume division of renowned toy manufacturer JAKKS Pacific, Inc. (NASDAQ: JAKK), is thrilled to announce an expanded licensing agreement with Aniplex Inc. This collaboration centers around the immensely popular anime and manga franchise, Demon Slayer: Kimetsu no Yaiba. New Licensing Terms...

Continue Reading
Jay Atlas: A Decade of Activism and Hope on the Road

Updated Category News Views 479

Reflecting on a Decade of Activism Where do you feel you truly thrive? This thought-provoking question from a therapist leads Joshua “Jay” Atlas to ponder his life and the impact he’s made. As the Operation Manager for Bio-One Philly and a committed community advocate, he finds fulfillment in helping others, even while navigating his own challenges. Discovering...

Continue Reading
Investors Urged to Join Petco Class Action Against Securities Fraud

Updated Category News Views 168

Investors Encouraged to Take Action Against Petco's Securities Fraud Faruqi & Faruqi, LLP, a respected name in securities law, is currently reaching out to all investors who may have experienced monetary losses exceeding $100,000 with Petco Health and Wellness Company, Inc. (NASDAQ: WOOF). This is a significant opportunity for affected individuals to engage and seek...

Continue Reading
New Leadership Changes in KN Energies' Nomination Committee

Updated Category News Views 166

New Leadership Changes in KN Energies' Nomination Committee AB „KN Energies“ has recently made significant changes to its Remuneration and Nomination Committee, reflecting their commitment to strong governance and leadership. The Supervisory Council of the company has appointed a new member who will play a crucial role in guiding the company's executive decisions....

Continue Reading
Skye Bioscience Welcomes New Chairman Paul Grayson for Growth

Updated Category News Views 233

Skye Bioscience Welcomes New Leadership Skye Bioscience, Inc. (NASDAQ: SKYE), a forefront clinical-stage biopharmaceutical firm, has recently appointed Paul Grayson as the new Chairman of the Board. This significant change is aimed at reinforcing governance structures and enhancing oversight capabilities as the company navigates through its developmental phases. Paul...

Continue Reading